USP and Public Policy
Left
Refine Your Search
In response to the request from the Commission of Analytical Control and Expansion of Coverage (CCAYAC) within Mexico’s Federal Commission for the Protection against Sanitary Risk (COFEPRIS), this…
Learn More
USP appreciates this opportunity to submit comments on FDA’s Draft Guidance on Hazard Analysis and Risk-Based Preventive Controls for Human Food (HARPC Draft Guidance).
Learn More
USP appreciates the opportunity to comment on the Food and Drug Administration's (FDA) issuance of the List of Bulk Drug Substances That Can Be Used To Compound Drug Products in Accordance With…
Learn More
USP welcomes this opportunity to submit comments on FDA’s planned development of a list of pre-Dietary Supplement Health and Education Act ingredients (preDSHEA list).
Learn More
USP appreciates this opportunity to submit comments on FDA’s final rule on the criteria for substances that are generally recognized as safe (GRAS) and on the GRAS notification process.
Learn More
USP appreciates this opportunity to submit comments on the ISO proposal for a new field of technical activity – Medicinal Plants.
Learn More
USP appreciates this opportunity to submit comments on FDA’s revised Draft Guidance on New Dietary Ingredient (NDI) Notifications and Related Issues (Revised Draft Guidance), issued on August 12,…
Learn More
USP welcomes the Food and Drug Administration’s (FDA) issuance of the draft guidance, “Elemental Impurities in Drug Products Guidance for Industry." This draft guidance provides clarity and…
Learn More
USP appreciates the opportunity to comment on the Food and Drug Administration's (FDA) "Request for Quality Metrics Draft Guidance for Industry" (Quality Metrics Draft Guidance). We…
Learn More
USP appreciates the opportunity to comment on the Food and Drug Administration's (FDA) "Nonproprietary Naming of Biological Products" Draft Guidance for Industry" (Draft Guidance).
Learn More